Selected research
Industry Research
Genetic Testing For Neurological Disorders Industry Research Report 2026
Market perspective
The global Genetic Testing For Neurological Disorders market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Genetic Testing For Neurological Disorders market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Genetic Testing For Neurological Disorders market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Genetic Testing For Neurological Disorders market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Genetic Testing For Neurological Disorders include Illumina, CENTOGENE, Victorian Clinical Genetics Services, PacBio, Mayo Clinic, Quest Diagnostics, MedGenome Labs, GeneDx and Connecticut Children's and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Genetic Testing For Neurological Disorders market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Genetic Testing For Neurological Disorders.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Genetic Testing For Neurological Disorders Market by Company
Illumina
CENTOGENE
Victorian Clinical Genetics Services
PacBio
Mayo Clinic
Quest Diagnostics
MedGenome Labs
GeneDx
Connecticut Children's
Labcorp (Invitae/MNG Laboratories)
Genetic Testing For Neurological Disorders Segment by Type
Exome Sequencing
Whole Genome Sequencing
RNA Sequencing
General DNA Testing
Genetic Testing For Neurological Disorders Segment by Application
Hospitals
Specialty Clinics
Diagnostics Laboratories
Genetic Testing For Neurological Disorders Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Genetic Testing For Neurological Disorders market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Genetic Testing For Neurological Disorders and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Genetic Testing For Neurological Disorders.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Genetic Testing For Neurological Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Exome Sequencing
- Whole Genome Sequencing
- RNA Sequencing
- General DNA Testing
Applications
- Hospitals
- Specialty Clinics
- Diagnostics Laboratories
Companies covered
- Illumina
- CENTOGENE
- Victorian Clinical Genetics Services
- PacBio
- Mayo Clinic
- Quest Diagnostics
- MedGenome Labs
- GeneDx
- Connecticut Children's
- Labcorp (Invitae/MNG Laboratories)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Genetic Testing For Neurological Disorders by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Exome Sequencing
- 2.2.3 Whole Genome Sequencing
- 2.2.4 RNA Sequencing
- 2.2.5 General DNA Testing
- 2.3 Genetic Testing For Neurological Disorders by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals
- 2.3.3 Specialty Clinics
- 2.3.4 Diagnostics Laboratories
- 2.4 Assumptions and Limitations
3 Genetic Testing For Neurological Disorders Breakdown Data by Type
- 3.1 Global Genetic Testing For Neurological Disorders Historic Market Size by Type (2021-2026)
- 3.2 Global Genetic Testing For Neurological Disorders Forecasted Market Size by Type (2027-2032)
4 Genetic Testing For Neurological Disorders Breakdown Data by Application
- 4.1 Global Genetic Testing For Neurological Disorders Historic Market Size by Application (2021-2026)
- 4.2 Global Genetic Testing For Neurological Disorders Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Genetic Testing For Neurological Disorders Market Perspective (2021-2032)
- 5.2 Global Genetic Testing For Neurological Disorders Growth Trends by Region
- 5.2.1 Global Genetic Testing For Neurological Disorders Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Genetic Testing For Neurological Disorders Historic Market Size by Region (2021-2026)
- 5.2.3 Genetic Testing For Neurological Disorders Forecasted Market Size by Region (2027-2032)
- 5.3 Genetic Testing For Neurological Disorders Market Dynamics
- 5.3.1 Genetic Testing For Neurological Disorders Industry Trends
- 5.3.2 Genetic Testing For Neurological Disorders Market Drivers
- 5.3.3 Genetic Testing For Neurological Disorders Market Challenges
- 5.3.4 Genetic Testing For Neurological Disorders Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Genetic Testing For Neurological Disorders Players by Revenue
- 6.1.1 Global Top Genetic Testing For Neurological Disorders Players by Revenue (2021-2026)
- 6.1.2 Global Genetic Testing For Neurological Disorders Revenue Market Share by Players (2021-2026)
- 6.2 Global Genetic Testing For Neurological Disorders Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Genetic Testing For Neurological Disorders Head Office and Area Served
- 6.4 Global Genetic Testing For Neurological Disorders Players, Product Type & Application
- 6.5 Global Genetic Testing For Neurological Disorders Manufacturers Established Date
- 6.6 Global Genetic Testing For Neurological Disorders Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Genetic Testing For Neurological Disorders Market Size (2021-2032)
- 7.2 North America Genetic Testing For Neurological Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Genetic Testing For Neurological Disorders Market Size by Country (2021-2026)
- 7.4 North America Genetic Testing For Neurological Disorders Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Genetic Testing For Neurological Disorders Market Size (2021-2032)
- 8.2 Europe Genetic Testing For Neurological Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Genetic Testing For Neurological Disorders Market Size by Country (2021-2026)
- 8.4 Europe Genetic Testing For Neurological Disorders Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Genetic Testing For Neurological Disorders Market Size (2021-2032)
- 9.2 Asia-Pacific Genetic Testing For Neurological Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Genetic Testing For Neurological Disorders Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Genetic Testing For Neurological Disorders Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Genetic Testing For Neurological Disorders Market Size (2021-2032)
- 10.2 South America Genetic Testing For Neurological Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Genetic Testing For Neurological Disorders Market Size by Country (2021-2026)
- 10.4 South America Genetic Testing For Neurological Disorders Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Genetic Testing For Neurological Disorders Market Size (2021-2032)
- 11.2 Middle East & Africa Genetic Testing For Neurological Disorders Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Genetic Testing For Neurological Disorders Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Genetic Testing For Neurological Disorders Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Illumina
- 12.1.1 Illumina Company Information
- 12.1.2 Illumina Business Overview
- 12.1.3 Illumina Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.1.4 Illumina Genetic Testing For Neurological Disorders Product Portfolio
- 12.1.5 Illumina Recent Developments
- 12.2 CENTOGENE
- 12.2.1 CENTOGENE Company Information
- 12.2.2 CENTOGENE Business Overview
- 12.2.3 CENTOGENE Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.2.4 CENTOGENE Genetic Testing For Neurological Disorders Product Portfolio
- 12.2.5 CENTOGENE Recent Developments
- 12.3 Victorian Clinical Genetics Services
- 12.3.1 Victorian Clinical Genetics Services Company Information
- 12.3.2 Victorian Clinical Genetics Services Business Overview
- 12.3.3 Victorian Clinical Genetics Services Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.3.4 Victorian Clinical Genetics Services Genetic Testing For Neurological Disorders Product Portfolio
- 12.3.5 Victorian Clinical Genetics Services Recent Developments
- 12.4 PacBio
- 12.4.1 PacBio Company Information
- 12.4.2 PacBio Business Overview
- 12.4.3 PacBio Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.4.4 PacBio Genetic Testing For Neurological Disorders Product Portfolio
- 12.4.5 PacBio Recent Developments
- 12.5 Mayo Clinic
- 12.5.1 Mayo Clinic Company Information
- 12.5.2 Mayo Clinic Business Overview
- 12.5.3 Mayo Clinic Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.5.4 Mayo Clinic Genetic Testing For Neurological Disorders Product Portfolio
- 12.5.5 Mayo Clinic Recent Developments
- 12.6 Quest Diagnostics
- 12.6.1 Quest Diagnostics Company Information
- 12.6.2 Quest Diagnostics Business Overview
- 12.6.3 Quest Diagnostics Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.6.4 Quest Diagnostics Genetic Testing For Neurological Disorders Product Portfolio
- 12.6.5 Quest Diagnostics Recent Developments
- 12.7 MedGenome Labs
- 12.7.1 MedGenome Labs Company Information
- 12.7.2 MedGenome Labs Business Overview
- 12.7.3 MedGenome Labs Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.7.4 MedGenome Labs Genetic Testing For Neurological Disorders Product Portfolio
- 12.7.5 MedGenome Labs Recent Developments
- 12.8 GeneDx
- 12.8.1 GeneDx Company Information
- 12.8.2 GeneDx Business Overview
- 12.8.3 GeneDx Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.8.4 GeneDx Genetic Testing For Neurological Disorders Product Portfolio
- 12.8.5 GeneDx Recent Developments
- 12.9 Connecticut Children's
- 12.9.1 Connecticut Children's Company Information
- 12.9.2 Connecticut Children's Business Overview
- 12.9.3 Connecticut Children's Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.9.4 Connecticut Children's Genetic Testing For Neurological Disorders Product Portfolio
- 12.9.5 Connecticut Children's Recent Developments
- 12.10 Labcorp (Invitae/MNG Laboratories)
- 12.10.1 Labcorp (Invitae/MNG Laboratories) Company Information
- 12.10.2 Labcorp (Invitae/MNG Laboratories) Business Overview
- 12.10.3 Labcorp (Invitae/MNG Laboratories) Revenue in Genetic Testing For Neurological Disorders Business (2021-2026)
- 12.10.4 Labcorp (Invitae/MNG Laboratories) Genetic Testing For Neurological Disorders Product Portfolio
- 12.10.5 Labcorp (Invitae/MNG Laboratories) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst